Antigen-specific suppression of inflammatory arthritis using liposomes

Journal of Immunology

Volumn 182, Issue 6, 2009, Pages 3556-3565

  Capini, Christelle ^a   Jaturanpinyo, Montree ^a,b   Chang, Hsin I ^a   Mutalik, Srinivas ^a   McNally, Alice ^a   Street, Shayna ^a   Steptoe, Raymond ^a   O'Sullivan, Brendan ^a   Davies, Nigel ^a   Thomas, Ranjeny ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; BOVINE SERUM ALBUMIN; CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; LIPOSOME; OVALBUMIN; PHOSPHATIDYLCHOLINE; QUERCETIN; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; DRUG CARRIER; EPITOPE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; NITRILE; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONE;

ALLERGIC DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EGG; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATORY ARTHRITIS; INFLAMMATORY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG ANTAGONISM; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CURCUMIN; DRUG CARRIERS; EPITOPES; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B; NITRILES; OVALBUMIN; QUERCETIN; SERUM ALBUMIN, BOVINE; SULFONES;

EID: 65449183747     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802972     Document Type: Article

References (38)

1. Wolfe, F., K. Michaud, B. Stephenson, and J. Doyle. 2003. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate. J. Rheumatol. 30: 1725-1732.
2. Hyrich, K. L., M. Lunt, W. G. Dixon, K. D. Watson, and D. P. Symmons. 2008. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 47: 1000-1005.
3. Schellekens, G. A., H. Visser, B. A. de Jong, F. H. van den Hoogen, J. M. Hazes, F. C. Breedveld, and W. J. van Venrooij. 2000. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43: 155-163.
4. Dittel, B. N., I. Visintin, R. M. Merchant, and C. A. Janeway, Jr. 1999. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J. Immunol. 163: 32-39.
5. Lutzky, V., S. Hannawi, and R. Thomas. 2007. Cells of the synovium in rheumatoid arthritis: dendritic cells. Arthritis Res. Ther. 9: 219.
6. O'Sullivan, B. J., and R. Thomas. 2002. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-κB. J. Immunol. 168: 5491-5498.
7. Martin, E., B. O'Sullivan, P. Low, and R. Thomas. 2003. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18: 155-167.
8. Thompson, A. G., B. J. O'Sullivan, H. Beamish, and R. Thomas. 2004. T cells signaled by NF-κB-dendritic cells are sensitized not anergic to subsequent activation. J. Immunol. 173: 1671-1680.
9. Martin, E., C. Capini, E. Duggan, V. P. Lutzky, P. Stumbles, A. R. Pettit, B. O'Sullivan, and R. Thomas. 2007. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-κB. Arthritis Rheum. 56: 2255-2266.
10. Claassen, E. 1992. Post-formation fluorescent labelling of liposomal membranes: in vivo detection, localisation and kinetics. J. Immunol. Methods 147: 231-240.
11. Pettit, A. R., C. Quinn, K. P. MacDonald, L. L. Cavanagh, G. Thomas, W. Townsend, M. Handel, and R. Thomas. 1997. Nuclear localization of RelB is associated with effective antigen-presenting cell function. J. Immunol. 159: 3681-3691.
12. Pierce, J. W., R. Schoenleber, G. Jesmok, J. Best, S. A. Moore, T. Collins, and M. E. Gerritsen. 1997. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272: 21096-21103.
13. Kim, G. Y., K. H. Kim, S. H. Lee, M. S. Yoon, H. J. Lee, D. O. Moon, C. M. Lee, S. C. Ahn, Y. C. Park, and Y. M. Park. 2005. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-αB as potential targets. J. Immunol. 174: 8116-8124.
14. Kim, B. H., S. M. Cho, A. M. Reddy, Y. S. Kim, K. R. Min, and Y. Kim. 2005. Down-regulatory effect of quercitrin gallate on nuclear factor-κB-dependent inducible nitric oxide synthase expression in lipopolysaccharide-stimulated macrophages RAW 264.7. Biochem. Pharmacol. 69: 1577-1583.
15. Pulendran, B., J. Lingappa, M. K. Kennedy, J. Smith, M. Teepe, A. Rudensky, C. R. Maliszewski, and E. Maraskovsky. 1997. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J. Immunol. 159: 2222-2231.
16. Vremec, D., M. Zorbas, R. Scollay, D. J. Saunders, C. F. Ardavin, L. Wu, and K. Shortman. 1992. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176: 47-58.
17. Vremec, D., J. Pooley, H. Hochrein, L. Wu, and K. Shortman. 2000. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164: 2978-2986.
18. + cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194: 1171-1178.
19. Blasius, A. L., E. Giurisato, M. Cella, R. D. Schreiber, A. S. Shaw, and M. Colonna. 2006. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 177: 3260-3265.
20. + T cell tolerance. J. Exp. Med. 196: 1627-1638.
21. Hawiger, D., K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M. Rivera, J. V. Rauetch, R. M. Steinman, and M. C. Nussenzweig. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769-780.
22. Lohr, J., B. Knoechel, E. C. Kahn, and A. K. Abbas. 2004. Role of B7 in T cell tolerance. J. Immunol. 173: 5028-5035.
23. + regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101: 4862-4869.
24. + T cells. J. Immunol. 178: 2094-2103.
25. + regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J. Exp. Med. 196: 247-253.
26. - cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J. Immunol. 172: 5213-5221.
27. Brackertz, D., G. Mitchell, and I. R. Mackay. 1977. Antigen-induced arthritis in mice. Arthritis Rheum. 20: 841-850.
28. Li, M., X. Zhang, X. Zheng, D. Lian, Z. X. Zhang, W. Ge, J. Yang, C. Vladau, M. Suzuki, D. Chen, et al. 2007. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J. Immunol. 178: 5480-5487.
29. Moore, F., S. Buonocore, E. Aksoy, N. Ouled-Haddou, S. Goriely, E. Lazarova, F. Paulart, C. Heirman, E. Vaeremans, K. Thielemans, et al. 2007. An alternative pathway of NF-κB activation results in maturation and T cell priming activity of dendritic cells overexpressing a mutated IκBα. J. Immunol. 178: 1301-1311.
30. Oussoren, C., M. Velinova, G. Scherphof, J. J. van der Want, N. van Rooijen, and G. Storm. 1998. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: IV. Fate of liposomes in regional lymph nodes. Biochim. Biophys. Acta 1370: 259-272.
31. Li, L., B. Ahmed, K. Mehta, and R. Kurzrock. 2007. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol. Cancer Ther. 6: 1276-1282.
32. Thangapazham, R. L., A. Puri, S. Tele, R. Blumenthal, and R. K. Maheshwari. 2008. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int. J. Oncol. 32: 1119-1123.
33. Sharma, R. A., S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, et al. 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 10: 6847-6854.
34. Sandur, S. K., M. K. Pandey, B. Sung, K. S. Ahn, A. Murakami, G. Sethi, P. Limtrakul, V. Badmaev, and B. B. Aggarwal. 2007. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 28: 1765-1773.
35. Strasser, E. M., B. Wessner, N. Manhart, and E. Roth. 2005. The relationship between the anti-inflammatory effects of curcumin and cellular glutathione content in myelomonocytic cells. Biochem. Pharmacol. 70: 552-559.
36. van der Helm-van Mil, A. H., K. N. Verpoort, F. C. Breedveld, T. W. Huizinga, R. E. Toes, and R. R. de Vries. 2006. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 54: 1117-1121.
37. Hill, J. A., D. A. Bell, W. Brintnell, D. Yue, B. Wehrli, A. M. Jevnikar, D. M. Lee, W. Hueber, W. H. Robinson, and E. Cairns. 2008. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J. Exp. Med. 205: 967-979.
38. Kuhn, K. A., L. Kulik, B. Tomooka, K. J. Braschler, W. P. Arend, W. H. Robinson, and V. M. Holers. 2006. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 116: 961-973.